Save the date! On September 26-27th, 2024, the 5th International Symposium on Regulatory Autoantibodies will take place in Lübeck! Under the direction of Prof. Dr. med. Gabriela Riemekasten, excellent speakers such as Prof. Dr. Carmen Scheibenbogen, Prof. Yehuda Shoenfeld and others will focus on the connection of RABs to the pathogenesis of diseases and their…
DetailsOn August 27, the Federal Minister of Health, Prof. Karl Lauterbach, visited our company to find out about the research work on ME/CSF and the therapeutic options based on it. There was a stimulating exchange of ideas. Afterwards, the Minister posted on X: “(…) one of the most exciting developments towards a therapy for ME/CFS.…
DetailsCellTrend has introduced a quality management system in order to meet the high quality standards of our customers. This quality management system is audited annually by an independent institute. Once again this year, the TÜV Rheinland certification body has certified that CellTrend GmbH applies the quality management system and meets the requirements of the EN…
DetailsA shocking article about the biggest medical scandal was written by George Monbiot, a columnist for the Guardian. He wrote about the decades-long mistreatment of ME/CFS patients. People with this devastating disease were told they were work-shy and that their symptoms were imaginary. Graded Exercise Therapy (GET) and Cognitive Behavioral Therapy (CBT) became the official…
DetailsPlease note that our laboratory will be closed for an extended weekend due to the public holiday on 09.05.2024! Please only send samples that reach our laboratory by Wednesday, 08.05.24. Samples will not be accepted at the weekend. From 13.05.24 we will be there for you again as usual.
DetailsAccording to Fatigatio e.V., the determination of autoantibodies against ß1 and ß2 adrenergic receptors, as well as against M3 and M4 acetylcholine receptors can round off the diagnostic process to ME/CFS. Together with Prof. Dr. Carmen Scheibenbogen (Charité), CellTrend developed and validated this test system. For more information, please have a look at: this site!
In 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Medicine for the discovery of a tumor therapy through negative immune regulation. Here, the binding between PD1 (Programmed cell death protein 1) and PD-L1 (Programmed cell death protein 1 ligand) is inhibited. CellTrend has discovered autoantibodies against PD1 and PD-L1 in tumor…
DetailsOn January 10, 2024, Member of the Bundestag Sylvia Lehmann (direct mandate of the constituency) visited CellTrend and was informed about autoantibody diagnostics.
DetailsA new study about severity of neurological Long-COVID symptoms and their correlation with the increased level of autoantibodies was published. In Table 1 you can have a look at the 200 individuals which were recruited and put into 3 groups. One group with 72 patients were diagnosed with Long-COVID, second group with 58 patients had…
DetailsWe wish you a Merry Christmas and a Happy New Year 2024! Please note that our laboratory will be closed from 23.12.23 until 01.01.2024 due to the Christmas holidays. During this period, patient samples will not be accepted! The last diagnostics of the patient samples will take place on 14.12.2023! From 02.01.2024 we…
Details
